Although the detailed mechanism underlying the therapeutic effects of ribitol supplementation in FKRP-deficient cases remains unclear, CDP-Rbo supplementation therapy could also be applicable to Fukutin- or FKRP-deficient muscular dystrophies if increased CDP-Rbo levels could enhance the residual RboP-transferase activities of Fukutin or FKRP mutant proteins. The gene discussed is FKRP; the disease is muscular dystrophy.